Financial
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Isla Health
HQ United Kingdom · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Not assessed
Customer rating
No reviews yet
Financial health
Band: Not assessedPrivately held
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
No adverse media involving Isla Health found in HSH's search of the last 24 months.
Cyber & information governance
No data breaches, cyber incidents or regulator action involving Isla Health found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
No product recalls, safety notices or clinical safety actions involving Isla Health found in HSH's search of the last 24 months.
Contract performance
Aug 2025: NHS England awarded Isla Health a direct contract worth about £98,000 (ex VAT), running Sep 2025 to Aug 2026, for routine PSA surveillance of men at higher risk of prostate cancer. In Feb 2025 it partnered with the Rotunda Hospital, Dublin.
Competitors
No competitors linked yet.